Corautus Genetics Inc.
Corautus Genetics receives NASDAQ deficiency notice related to minimum bid price
Published in Genetics and Environmental Business Week, June 29th, 2006
Corautus Genetics Inc. (VEGF), a clinical stage biopharmaceutical company dedicated to the development of new and innovative gene therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease, announced that it received a deficiency letter from The NASDAQ Stock Market indicating that it is not in compliance with the continued listing requirements on the NASDAQ Capital Market because for the previous 30 consecutive business days the bid price of its common stock had closed below the $1.00 minimum per share requirement for continued listing as set forth in Marketplace Rule 4310(c)(4).
It is NASDAQ's customary practice to issue a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
More Articles from Genetics and Environmental Business Week
- AstraZeneca
AstraZeneca invests $100M in China research and development - DNAPrint Genomics, Inc.
DNAPrint Genomics updates first quarter business activity - University Hospitals of Cleveland
University Hospitals of Cleveland receives $250,000 grant for breast cancer research - Addenbrooke's Hospital, Cambridge, England
Researchers' findings from the United Kingdom, Germany and South Korea advance genetics research - Alberta Children's Hospital
Dilated cardiomyopathy with ataxia syndrome is caused by mutation of DNAJC19 - American Association for the Study of Liver Diseases
Education and guidelines needed for genetic testing in liver disease - More from this issue of Genetics and Environmental Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
